Focus sur les présentations du Centre Antoine Lacassagne au Congrès annuel de l’European Society of Medical Oncology

Deux présentations orales

Samedi 19 septembre : 12:30 – 12:42 LBA38 – Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial
Co-auteur: Pr Joël Guigay

 Lundi 21 septembre : 16:20 – 16:22 LBA25 – Results from the phase 2 BIOmarker driven trial with Nivolumab (N) and Ipilimumab or VEGFR tyrosine Kinase inhibitor (TKI) in naïve metastatic Kidney cancer (m-ccRCC) patients (pts): the BIONIKK trial.
Co-auteur: Dr Delphine Borchiellini

Une « mini-oral » présentation

Vendredi 18 septembre: Clinical relevance of MIR27A rs895819 polymorphism and its interaction with DPYD variants for predicting grade 4-5 fluoropyrimidine toxicity in the FUSAFE individual patient data meta-analysis“- Abstract #1846 – Session Gastro Intestinal
Premier auteur: Marie-Christine Etienne-Grimaldi

13 posters :

1691P – Evaluation of practice variation for cancer patients care in a French cancer center during the COVID-19 outbreak
Premier auteur : Dr Delphine Borchiellini 

920P – Avelumab (anti-PD-L1) in patients with platinum-refractory/ineligible recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Results from a phase Ib cohort
Premier auteur : Pr Joël Guigay 

946P – Germinal immunogenetics and response to nivolumab in recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC) patients (pts): TopNIVO ancillary study
Premier auteur : Dr Esma B. Saada 

735P – Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: A multicentric retrospective study
Co- auteur : Dr Delphine Borchiellini

788P – Urachal carcinoma: Large retrospective multicentric GETUG-AFU study
Co- auteur : Dr Delphine Borchiellini 

1059P – NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Co- auteur : Dr Delphine Borchiellini 

PRODIGE 65 – UCGI 36 – GEMPAX : a unicancer phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after folfirinox failure or intolerance in metastatic pancreatic ductal adenocarcinoma
Co- auteur : Dr Ludovic Evesque

Age and pathological complete response after neoadjuvant chemoradiation (CRT) with or without oxaliplatin in locally advanced rectal cancer (larc): individual patient data (IPD) meta-analysis of three randomised trials (RTS)
Co- auteur : Pr Jean-Pierre Gérard

Real-life management and prognosis of young women (≤ 40 yo) with de novo metastatic breast cancer in the multicenter national observational ESME program
Co- auteur : Pr Jean-Marc Ferrero

METASYN: patterns of care and outcomes of 387 metastatic synovial sarcoma: real-life data from the french sarcoma group (GSF/GETO)
Co- auteur : Dr Esma B. Saada 

Efficacy of 2nd line treatment with chemotherapy (CT) or immune checkpoint inhibitors (ICIS) for patients (PTS) with a prolonged objective response (>6 months) after 1st line therapy for recurrent or metastatic head & neck squamous cell carcinoma (R/M-HNSCC)
Co- auteur : Dr Esma B. Saada 

Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): efficacy and safety data from ifct-1803 LORLATU expanded access program (EAP) cohort
Co- auteur : Dr Josiane Otto

Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
Co- auteur : Dr Josiane Otto